Respiri Limited (AU:RSH) has released an update.
Respiri Limited is making strides in the US healthcare market with its innovative eHealth solutions, inviting investors to a webinar to discuss recent achievements and future goals. Known for its cutting-edge technology like the FDA-approved wheezo® device, Respiri is focused on transforming chronic disease management through remote patient monitoring. As the company aims for a cash flow positive outcome by the end of 2024, its strategic partnerships and advanced programs are set to reduce healthcare costs and improve patient care.
For further insights into AU:RSH stock, check out TipRanks’ Stock Analysis page.
